New study observes Real-World progress of kidney disease treatment

NCT ID NCT06242327

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 500 adults with primary membranous nephropathy and nephrotic syndrome who are treated with rituximab or other monoclonal antibodies. Researchers aim to describe long-term disease outcomes and identify predictors of remission or progression. The study does not test a new treatment but gathers real-world data to improve understanding of current therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • ASST HPG23 - Unità di Nefrologia

    ACTIVE_NOT_RECRUITING

    Bergamo, BG, 24127, Italy

  • Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"

    RECRUITING

    Ranica, BG, 24020, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••